ArticleJournal of cellular and molecular medicine2025
Hypoxia Combined With Interleukin-17 Regulates Hypoxia-Inducible Factor-1α/Endothelial Nitric Oxide Synthase Expression in Pulmonary Artery Endothelial Cells.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The pathogenesis of chronic thromboembolic pulmonary hypertension may be multifactorial and requires further studies. We explored alterations in pulmonary artery endothelial cells under the hypoxic and elevated interleukin-17 conditions that are commonly present in patients with chronic thromboembolic pulmonary hypertension. We measured the serum interleukin-17 levels in 10 chronic thromboembolic pulmonary hypertension patients and 10 healthy control persons. The expressions and localisations of hypoxia-inducible factor-1α and endothelial nitric oxide synthase were detected in tissues. The levels of hypoxia-inducible factor-1α, endothelial nitric oxide synthase, nitric oxide, and reactive oxygen species in cultured pulmonary artery endothelial cells were examined under hypoxia and/or interleukin-17 treatment. The serum interleukin-17 level was increased in chronic thromboembolic pulmonary hypertension patients. Hypoxia-inducible factor-1α was increased, and endothelial nitric oxide synthase was decreased in chronic thromboembolic pulmonary hypertension pulmonary vascular tissue. After receiving the hypoxia combined with interleukin-17 treatment, pulmonary artery endothelial cells showed increased levels of hypoxia-inducible factor-1α and phospho-endothelial nitric oxide synthase (Thr495) (p = 0.001 and 0.063, respectively) and a decreased level of endothelial nitric oxide synthase (p < 0.001). In addition, the nitric oxide level was significantly decreased (p = 0.001), whereas the reactive oxygen species level was insignificantly increased in pulmonary artery endothelial cells. Chronic thromboembolic pulmonary hypertension patients might experience increased inflammation and hypoxia due to dysregulation of the hypoxia-inducible factor-1α/endothelial nitric synthase pathway in pulmonary artery endothelial cells under inflammation and hypoxia, contributing to the pathogenesis of chronic thromboembolic pulmonary hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.